Rep. April McClain Delaney Buys Laboratory Co. of America Holdings (NYSE:LH) Shares

Representative April McClain Delaney (D-Maryland) recently bought shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on March 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Revvity (NYSE:RVTY) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of Laboratory Co. of America (NYSE:LH) on 2/28/2025.
• Purchased $15,001 – $50,000 in shares of Corpay (NYSE:CPAY) on 2/28/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/27/2025.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 2/22/2025.
• Purchased $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/22/2025.

Laboratory Co. of America Stock Performance

LH stock opened at $233.97 on Friday. The stock has a 50-day moving average price of $245.16 and a 200-day moving average price of $234.31. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The firm has a market cap of $19.58 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 1.71 and a beta of 1.12.

Laboratory Co. of America (NYSE:LH) last issued its earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, equities research analysts expect that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.23%. The ex-dividend date was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 32.65%.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares of the company’s stock, valued at approximately $21,146,175.90. The trade was a 6.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kerrii B. Anderson sold 500 shares of Laboratory Co. of America stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $255.63, for a total transaction of $127,815.00. Following the completion of the sale, the director now directly owns 13,166 shares in the company, valued at $3,365,624.58. This trade represents a 3.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,500 shares of company stock valued at $3,577,572 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on LH shares. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their target price for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Citigroup upgraded Laboratory Co. of America from a “neutral” rating to a “buy” rating and raised their target price for the company from $250.00 to $300.00 in a research note on Tuesday, March 4th. Piper Sandler raised their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. UBS Group reduced their target price on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $268.38.

Hedge Funds Weigh In On Laboratory Co. of America

Several hedge funds have recently modified their holdings of the company. Private Trust Co. NA lifted its position in shares of Laboratory Co. of America by 3.2% during the 3rd quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock worth $300,000 after buying an additional 41 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Laboratory Co. of America by 0.5% during the 4th quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company’s stock worth $1,840,000 after buying an additional 43 shares in the last quarter. SP Asset Management LLC lifted its position in shares of Laboratory Co. of America by 0.3% during the 4th quarter. SP Asset Management LLC now owns 15,186 shares of the medical research company’s stock worth $3,483,000 after buying an additional 43 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Laboratory Co. of America by 0.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,780 shares of the medical research company’s stock worth $2,931,000 after buying an additional 45 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of Laboratory Co. of America by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,194 shares of the medical research company’s stock worth $1,650,000 after buying an additional 46 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.